H.C. Wainwright lowered the firm’s price target on Aclaris Therapeutics to $9 from $43 and keeps a Buy rating on the shares after the zunsemetinib Phase 2b rheumatoid arthritis trial failed to meet primary or secondary endpoints. The analyst removed zunsemetinib from its valuation assessment entirely, while reducing the probability of approval for ATI-1777 to 20% from 30%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ACRS:
- Aclaris Therapeutics downgraded after study failure at Cantor Fitzgerald
- Aclaris Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Aclaris Therapeutics price target lowered to $8 from $29 at BTIG
- Aclaris Therapeutics downgraded to Market Perform from Outperform at Leerink
- Aclaris Therapeutics downgraded to Neutral from Overweight at Piper Sandler